Spots Global Cancer Trial Database for Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy
Official Title: Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy
Study ID: NCT06222437
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.
Detailed Description: The study mainly focused for the following objectives: To determine the effect of semaglutide on ovulation and menstrual regularity. To determine the effect of semaglutide on androgen levels, namely testosterone, sex hormone binding globulin, and changes in hirsutism. To determine changes in weight, body mass index (BMI), and Glycated Hemoglobin( HbA1c) with semaglutide therapy.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Clinical Research Institute at Methodist Health System, Dallas, Texas, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
